Clariscan™

Clariscan™ (gadoteric acid) is a macrocyclic gadolinium-based contrast agent, expertly manufactured by GE HealthCare, used to enhance visualization in MRI procedures across a range of indications
Support
At a glance

Macrocyclic structure

Macrocyclic, ionic chelate provides high kinetic and themodynamic stability1

Expertly manufactured

Quality manufacture and delivery, expertly managed by GE HealthCare for greatest control

Established tolerability

Well-tolerated, with over 34 million patient administrations2

Convenient packaging options

Vials, and prefilled syringes in a range of volumes
ABOUT CLARISCAN

Clariscan is a macrocyclic, general-purpose GBCA. Used to enhance over 34 million MRI procedures globally since launch, Clariscan is manufactured in-house by GE HealthCare in a range of packaging options and has a well-established tolerability profile2,3,4,5

STRUCTURE

Gadoteric acid: the only macrocylic, ionic molecule

Stability refers to how tightly the gadolinium ion is bound to the chelating molecule and how likely it is to dissociate. Gadoteric acid is the only macrocyclic, ionic molecule across all gadoliunium-based contrast agents. In vitro data suggest that combining a macrocyclic structure for high kinetic stability, with ionicity for thermodynamic stability, may help to reduce the potential risk of gadolinium dissociation.1
INDICATIONS

A broad range of indications

Clariscan is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).6
PACKAGING

Meeting procedural needs, with packaging that prioritises your workplace safety and efficiency

Clariscan offers a range of packaging:
  • Glass vials: 5, 10, and 20 mL
  • Clear plastic prefilled syringes: 10, and 15 mL
COMMITMENT

Keeping production of Clariscan in-house, so you can be assured standards are maintained from start to finish

GE HealthCare has invested more than $370 million since 2019 to increase our manufacturing capacity and capability to meet growing demand for our contrast agents10. All our manufacturing sites are cGMP accredited.

Additional resources to support you

Access additional information to support you and your radiology team in the MRI department

Clariscan Case Studies in Brain MRI

Five use cases examine the results of Clariscan-enhanced MRI images in patients undergoing CNS Brain MRI scans

Download case studies

Clariscan Case Studies in Spine MRI

Six use cases examine the results of Clariscan-enhanced MRI images in patients undergoing CNS Spine MRI scans

Download case studies
REFERENCES
  1. 1. Port M et al. Biometals. 2008;21(4):469-490.
  2. 2. GE HealthCare Data on File, Safety Profile Clariscan November 2024
  3. 3. Jakobsen, Jarl Åsbjørn, et al. "Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study." BMC Medical Imaging 21.1 (2021): 74.
  4. 4. Behzadi, Ashkan Heshmatzadeh, and Jennifer McDonald. "Gadolinium-based contrast agents for imaging of the central nervous system: A multicenter European prospective study." Medicine 101.34 (2022): e30163.
  5. 5. Moon, Won-Jin, et al. "The Pattern of Use, Effectiveness, and Safety of Gadoteric Acid (Clariscan) in Patients Undergoing Contrast‐Enhanced Magnetic Resonance Imaging: A Prospective, Multicenter, Observational Study." Contrast Media & Molecular Imaging 2021.1 (2021): 4764348.
  6. 6. Clariscan Product Information, Australia and New Zealand.
  7. 7. Marshall G. Radiography 2008; 14: 128-34.
  8. 8. Gricar J et al. Radiol Manage 2007; SEP/OCT: 34-42.
  9. 9. Dhaliwal H et al. Int J Life Cycle Assess 2014; 19: 1965-73.
  10. 10. GE HealthCare Data on File, Investment 2023.

JB00015NZ 09-2025

JB01772AU